Cargando…
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Recent clinical trials using rapalogues in tuberous sclerosis complex (TSC) show regression in volume of typically vascularised tumours including angiomyolipomas (AMLs) and sub-ependymal giant cell astrocytomas (SEGAs). By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signall...
Autores principales: | Dodd, Kayleigh M., Yang, Jian, Shen, Ming Hong, Sampson, Julian R., Tee, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172452/ https://www.ncbi.nlm.nih.gov/pubmed/24931163 http://dx.doi.org/10.1038/onc.2014.164 |
Ejemplares similares
-
STAT3 and mTOR: co-operating to drive HIF and angiogenesis
por: Dodd, Kayleigh M., et al.
Publicado: (2015) -
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways
por: Kim, Boh-Ram, et al.
Publicado: (2014) -
Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma
por: Li, Ting, et al.
Publicado: (2020) -
The mTORC1 Effectors S6K1 and 4E-BP Play Different Roles in CNS Axon Regeneration
por: Yang, Liu, et al.
Publicado: (2014) -
Sensing of RNA stress by mTORC1 drives autoinflammation
por: Lee-Kirsch, Min Ae
Publicado: (2022)